Embryo Transfer — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Embryo transfer (ET) is the procedure that forms the final and decisive step of an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycle, in which one or more fertilised and cultured embryos are placed into the uterine cavity using a thin, flexible catheter passed through the cervix. After ovarian stimulation and egg retrieval, eggs are fertilised in the IVF laboratory and cultured for 3–5 days until they reach the cleavage (Day 3) or blastocyst (Day 5–6) stage. Blastocyst-stage transfer is now preferred at most fertility centres because extended culture allows selection of the most developmentally competent embryos and improves implantation rates per transfer. In a fresh embryo transfer, embryos are transferred in the same stimulation cycle as egg retrieval. In a frozen embryo transfer (FET) cycle, surplus embryos are vitrified (rapidly frozen) after the initial retrieval and transferred in a subsequent natural, modified natural, or hormone-prepared cycle when the endometrium is optimally prepared. FET outcomes have improved dramatically with vitrification technology — contemporary FET live birth rates often match or exceed fresh transfer rates, and some meta-analyses show a modest advantage for FET due to the avoidance of the supraphysiological hormonal environment of a stimulated cycle. Embryo transfer is a widely accessible and relatively simple procedure compared to other assisted reproductive technology (ART) steps.

Embryo transfer is the definitive step in all IVF and ICSI cycles and is therefore indicated for any couple or individual undergoing ART treatment. Underlying conditions necessitating IVF with embryo transfer include bilateral tubal factor infertility (fallopian tube damage or absence), male factor infertility with severely abnormal semen parameters requiring ICSI, endometriosis-related infertility, unexplained infertility after failure of simpler treatments (ovulation induction, intrauterine insemination), ovulatory dysfunction including polycystic ovarian syndrome (PCOS) unresponsive to oral ovulation induction, premature ovarian insufficiency requiring donor egg IVF, and age-related diminished ovarian reserve. Additional specific indications for embryo transfer include preimplantation genetic testing (PGT-A for aneuploidy screening, PGT-M for monogenic diseases) cycles where embryos are biopsied and chromosomally or genetically tested before transfer, gestational surrogacy arrangements where embryos are transferred to the uterus of a surrogate carrier, and embryo donation (recipients of donated embryos from third-party donors). Successful embryo transfer requires adequate endometrial receptivity — a trilaminar endometrial pattern with thickness of at least 7–8 mm at the time of transfer, assessed by transvaginal ultrasound.

Embryo transfer is a relatively painless outpatient procedure that typically requires no anaesthesia, though mild sedation is occasionally used if the patient has cervical stenosis or severe anxiety. The patient attends with a comfortably full bladder, which aids transabdominal ultrasound visualisation of the uterus and catheter trajectory. She lies supine in the lithotomy position. A speculum is inserted to expose the cervix, and the cervix is gently cleansed with warm culture medium. In the embryology laboratory adjacent to the procedure room, an embryologist selects the highest-quality embryo or embryos based on morphological grading (Gardner grading for blastocysts assesses inner cell mass quality and trophectoderm quality) or time-lapse imaging parameters. The selected embryo(s) are loaded into the tip of a soft, flexible transfer catheter (5–6 cm into the uterine cavity from the external os is the target position for optimal implantation). Under real-time transabdominal ultrasound guidance, the embryologist and clinician pass the catheter through the cervical canal into the uterine cavity, advancing 5–6 mm from the fundal wall to position the embryo optimally. The embryo(s) are deposited with a small volume of culture medium (typically 10–20 µL). The catheter is withdrawn slowly and immediately examined under the microscope by the embryologist to confirm no retained embryos. The entire process takes approximately 15–30 minutes.

Embryo transfer as the concluding step of IVF provides the potential for pregnancy in patients for whom natural conception is impossible or highly unlikely. Live birth rates per embryo transfer cycle vary substantially by age, embryo quality, endometrial receptivity, and technique. In women under 35 using their own eggs, live birth rates per fresh transfer average 35–50% in high-performing IVF units; this declines to approximately 20–30% at age 38–40 and 5–15% at age 42 and above. Frozen embryo transfer has equalised outcomes with fresh transfer: meta-analyses in 2022–2024 demonstrate equivalent live birth rates for FET in most patient groups, with potential superiority in women at risk of ovarian hyperstimulation syndrome (OHSS), where a freeze-all strategy eliminates OHSS risk while preserving cumulative success rates. Single embryo transfer (SET) — now the standard of care for women under 38 with at least one good-quality embryo — achieves live birth rates comparable to double embryo transfer in this group while eliminating the risk of twin pregnancy (which carries 5–7 times higher maternal and neonatal complication rates). Ultrasound-guided transfer improves implantation rates compared to clinical touch technique in randomised controlled trials, making image guidance standard practice.

Embryo transfer itself is a very low-risk procedure with a serious complication rate approaching zero. The main concerns associated with the IVF-embryo transfer process include: multiple pregnancy, arising when two or more embryos are transferred — while twin pregnancy is often perceived positively by patients, it carries a 5–7 fold increased risk of premature birth, perinatal mortality, maternal complications (pre-eclampsia, gestational diabetes), and neonatal intensive care admission. This is the primary rationale for the strong medical recommendation for single embryo transfer in good-prognosis patients. Ectopic implantation (implantation in the fallopian tube or on the cervix) occurs in approximately 2–3% of IVF pregnancies compared to 1–2% in natural conception, due to the underlying tubal disease that often prompted IVF treatment. Ovarian hyperstimulation syndrome (OHSS) affects up to 3–5% of stimulated cycles and, while not caused by the transfer itself, is relevant to fresh transfer decisions — severe OHSS (characterised by ascites, haemoconcentration, and thrombosis risk) is managed by postponing transfer and freezing all embryos for a future FET cycle. Mild post-transfer uterine cramping is common and benign. Failed implantation — the most common outcome — is not a procedural complication but reflects the biological limits of current implantation science; each failed transfer should be reviewed to optimise future cycles.

Evidence does not support mandatory bed rest after embryo transfer — multiple randomised controlled trials have demonstrated that enforced bed rest does not improve implantation or live birth rates compared to immediate normal activity resumption. Patients are advised to resume normal light activities immediately. Strenuous exercise (running, heavy gym sessions), sexual intercourse, hot baths, swimming, and excessive heat exposure are generally avoided for the first week as a precautionary measure. Progesterone supplementation — in the form of vaginal pessaries (e.g., Cyclogest 400 mg twice daily), intramuscular injections (Gestone), or subcutaneous injection (Prolutex) — is prescribed from the day of, or day after, egg retrieval and continues until the pregnancy test. If the test is positive, progesterone supplementation continues until 8–12 weeks of gestation. The 'two-week wait' — the 10–14 day interval between embryo transfer and the pregnancy blood test (quantitative serum beta-hCG) — is emotionally challenging; patients should be counselled that early pregnancy symptoms (breast tenderness, bloating, mild cramping) overlap extensively with progesterone side effects and are unreliable indicators of outcome. A positive hCG test is followed by a repeat test 48 hours later to confirm doubling, and then an early pregnancy ultrasound at 6–7 weeks gestation to confirm intrauterine location and cardiac activity.